ID   Ma-Mel-61b
AC   CVCL_C292
SY   MaMel61b
DR   cancercelllines; CVCL_C292
DR   Cosmic; 1846649
DR   Cosmic; 2686446
DR   ESTDAB; ESTDAB-219
DR   GEO; GSM2545594
DR   Progenetix; CVCL_C292
DR   Wikidata; Q54903829
RX   PubMed=23348503;
RX   PubMed=26909863;
RX   PubMed=28561041;
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Heterozygous (PubMed=26909863).
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Heterozygous (PubMed=26909863).
CC   Sequence variation: Gene deletion; HGNC; 6190; JAK1; Zygosity=Heterozygous (PubMed=28561041).
CC   Sequence variation: Gene fusion; HGNC; 7413; MTAP + HGNC; 34341; CDKN2B-AS1; Name(s)=MTAP-ANRIL (PubMed=26909863).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503).
CC   Omics: SNP array analysis.
CC   Derived from site: Metastatic; Cutaneous; UBERON=UBERON_0000014.
ST   Source(s): ESTDAB=ESTDAB-219
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 9,12
ST   D3S1358: 16
ST   D5S818: 11
ST   D7S820: 12
ST   FGA: 20
ST   TH01: 9,9.3
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_C291 ! Ma-Mel-61a
OI   CVCL_S666 ! Ma-Mel-61c
OI   CVCL_S667 ! Ma-Mel-61e
OI   CVCL_S668 ! Ma-Mel-61f
OI   CVCL_S669 ! Ma-Mel-61g
OI   CVCL_S670 ! Ma-Mel-61h
SX   Male
AG   29Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 02-05-24; Version: 16
//
RX   PubMed=23348503; DOI=10.1126/science.1230062;
RA   Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A.,
RA   Kadel S., Moll I., Nagore E., Hemminki K., Schadendorf D., Kumar R.;
RT   "TERT promoter mutations in familial and sporadic melanoma.";
RL   Science 339:959-961(2013).
//
RX   PubMed=26909863; DOI=10.18632/oncotarget.7503; PMCID=PMC4941330;
RA   Xie H.-P., Rachakonda P.S., Heidenreich B., Nagore E., Sucker A.,
RA   Hemminki K., Schadendorf D., Kumar R.;
RT   "Mapping of deletion breakpoints at the CDKN2A locus in melanoma:
RT   detection of MTAP-ANRIL fusion transcripts.";
RL   Oncotarget 7:16490-16504(2016).
//
RX   PubMed=28561041; DOI=10.1038/ncomms15440; PMCID=PMC5460020;
RA   Sucker A., Zhao F., Pieper N., Heeke C., Maltaner R., Stadtler N.,
RA   Real B., Bielefeld N., Howe S., Weide B., Gutzmer R., Utikal J.S.,
RA   Loquai C., Gogas H., Klein-Hitpass L., Zeschnigk M., Westendorf A.M.,
RA   Trilling M., Horn S., Schilling B., Schadendorf D., Griewank K.G.,
RA   Paschen A.;
RT   "Acquired IFNgamma resistance impairs anti-tumor immunity and gives
RT   rise to T-cell-resistant melanoma lesions.";
RL   Nat. Commun. 8:15440.1-15440.15(2017).
//